Comparative Pharmacology
Head-to-head clinical analysis: KOMBIGLYZE XR versus NESINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOMBIGLYZE XR versus NESINA.
KOMBIGLYZE XR vs NESINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
25 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Category C
Category C
DPP-4 Inhibitor + Biguanide Combination
DPP-4 Inhibitor